PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
Clinical Application of the 70-gene Profile: The MINDACT Trial
PUBLICATION: J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222. AUTHORS: Cardoso F., Van't Veer L., Rutgers E., Loi S., Mook S., Piccart-Gebhart M.J. SUMMARY: Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial, a 6,000-patient randomized, multicentric trial. This article reviews the Read More
Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort.
PUBLICATION: Clin Cancer Res. 2008 May 15;14(10):2988-93. doi: 10.1158/1078-0432.CCR-07-4723. AUTHORS: Wittner B.S., Sgroi D.C., Ryan P.D., Bruinsma T.J., Glas A.M., Male A., Dahiya S., Habin K., Bernards R., Haber D.A., Van't Veer L.J., Ramaswamy S. SUMMARY: The MammaPrint assay was originally designed to identify younger breast cancer patients at low Read More
Use of 70-gene Signature to Predict Prognosis of Patients with Node-Negative Breast Cancer: A Prospective Community-Based Feasibility Study (RASTER)
PUBLICATION: Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. AUTHORS: Bueno-de-Mesquita J.M., van Harten W.H., Retel V.P., van't Veer L.J., van Dam F.S., Karsenberg K., Douma K.F., van Tinteren H., Peterse J.L., Wesseling J., Wu T.S., Atsma D., Rutgers E.J., Brink G., Floore A.N., Glas A.M., Roumen R.M., Read More
Robust Interlaboratory Reproducibility of a Gene Expression Signature Measurement Consistent with the Needs of a New Generation of Diagnostic Tools
PUBLICATION: BMC Genomics. 2007 Jun 7;8:148. AUTHORS: Ach R.A., Floore A., Curry B., Lazar V., Glas A.M., Pover R., Tsalenko A., Ripoche H., Cardoso F., d'Assignies M.S., Bruhn L., Van't Veer L.J. SUMMARY: Despite this variation, measurement of one particular breast cancer gene expression signature in three different laboratories was Read More
Individualization of Therapy Using MammaPrint: from Development to the MINDACT Trial
PUBLICATION: Cancer Genomics & Proteomics. 2007 May-Jun;4(3):147-55. AUTHORS: Mook S., Van't Veer L.J., Rutgers E.J., Piccart-Gebhart M.J., Cardoso F. SUMMARY: A narrative review of the development and validation of MammaPrint. Read more: Mook et al_2007_Cancer Genomics & Proteomic_Individualization-of-Therapy
Converting a Breast Cancer Microarray Signature into a High-Throughput Diagnostic Test
PUBLICATION: BMC Genomics. 2006 Oct 30;7:278. AUTHORS: Glas A.M., Floore A., Delahaye L.J., Witteveen A.T., Pover R.C., Bakx N., Lahti-Domenici J.S., Bruinsma T.J., Warmoes M.O., Bernards R., Wessels L.F., Van't Veer L.J. SUMMARY: In this report, we demonstrate for the first time that microarray technology can be used as a Read More
Gene Expression Profiles of Primary Breast Carcinomas from Patients at High-Risk for Local Recurrence After Breast-Conserving Therapy
PUBLICATION: Clin Cancer Res. 2006 Oct 1;12(19):5705-12. AUTHORS: Kreike B., Halfwerk H., Kristel P., Glas A., Peterse H., Bartelink H., van de Vijver M.J. SUMMARY: No significant differences in gene expression between primary breast cancer tumors in patients with or without local recurrence after BCT were identified. Furthermore, analyses of Read More
